Trial Profile
A Phase II, Randomized, Double-blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Carcinoma Following Standard First or Second Line Endocrine Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs SR 16234 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 14 Dec 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 14 Dec 2012 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 01 Nov 2011 Results published in Cancer.